Navigation Links
CareToLive Reports: The FDA Fiddles While 30,000 Men Burn
Date:11/26/2007

DUBLIN, Ohio, Nov. 26 /PRNewswire/ -- /CTL/ -- CareToLive, a not for profit corporation, received a set back in a lower Federal Court last Wednesday in its fight against the FDA on behalf of terminal cancer patients. Undeterred, they announced that they will immediately file an appeal in the 6th Circuit Court in Ohio.

"Men are dying while a safe, effective treatment languishes outside of their grasp," said CareToLive spokesperson, Melody Davis. "Congress needs to wake up and hold hearings immediately! We are going to intensify our advocacy efforts on behalf of cancer patients. We feel the real reasons for the delay were financial and political conflicts. The FDA continues to ignore the cries of the 30,000 men dying of prostate cancer each year, and refuses to protect their health and well being as they are sworn to do."

"The evidence clearly shows our government violated these men's right to live," said Mike Kearney, a CareToLive board member. "They can say it, explain it, and infer it any way they want, but the truth is they allowed over 16,000 men to die since May 8th without treatment, while other men profited handsomely during their demise."

There has been only one approved treatment for late stage prostate cancer in over 42 years. The FDA decision was unprecedented in a late stage disease where the FDA special Advisory Panel of experts voted overwhelmingly that Provenge is safe and effective and no viable alternatives exist. Financially conflicted panel members, after failing to sabotage Provenge during the advisory meeting, "leaked" letters fraught with misinformation to improperly lobby FDA decision-makers and place public pressure on those decision-makers.

"The FDA makes up its rules as it goes along," Mr. Kearney continued, "and it does not follow its own rules, ignores congressional mandates and apparently answers to no one. The lower court indicated that the case is not reviewable as the FDA has not yet made a final deci
'/>"/>

SOURCE CareToLive
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related medicine news :

1. J.D. Power and Associates Reports: CIGNA HealthCare Recognized for Call Center Customer Satisfaction Excellence For a Second Consecutive Year
2. J.D. Power and Associates Reports: Hackensack University Medical Center Recognized as First Hospital to Achieve Distinction for Providing an Outstanding Inpatient Experience in All Four Service Areas
3. J.D. Power and Associates Reports: Rush-Copley Medical Center Recognized for Third Consecutive Year for Providing an Outstanding Inpatient Experience
4. Another Reason Not to Smoke While Pregnant: Birth Defects
5. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
6. Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize
7. Mecklenburg EMS Agency Launches Innovative Program to Pay Future EMTs While They Train
8. Former Congressman Hyde Awarded Presidential Medal of Freedom While Receiving Medical Rehabilitation at Marianjoy
9. Chronic kidney disease rises while most people with the condition remain unaware
10. 1 in 5 young Britons has sex with someone new while abroad
11. GNC Joins St. Jude Childrens Research Hospital(R) to Kick Off Fourth Annual Thanks And Giving(R) Campaign, Asking America to Help Save Childrens Lives While Shopping for the Holidays
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... along with the Japanese government and the Bill ... bolster Japan,s contribution to global health through the ... a press conference held as a side event ... Development (TICAD V). , Representatives from each of ... Labour and Welfare, the Ministry of Foreign Affairs, ...
(Date:6/19/2013)... Dental professionals are increasingly monitoring end tidal carbon ... sedation, a patient’s breathing depth and rate decrease. ... to update its guidelines to require etCO2 monitoring, or ... to increase safety in procedures. This amendment to Section ... effect July 1. , The Oregon Board of ...
(Date:6/19/2013)... Ariz. (PRWEB) June 19, 2013 PREFERRED ... WellCare of Arizona to offer a new ... Maricopa, Pima, La Paz, Yavapai and Mohave, Arizona counties. ... Mohave counties were effective January 1, 2013 and Maricopa ... 2014. , WellCare, Inc., the parent company of WellCare ...
(Date:6/19/2013)... Brightree LLC , the leading provider of cloud-based ... care industry, has been ranked for the first time - ... (HCI 100) list. This prestigious list features the top ... revenue during the last fiscal year. Since 2005, Brightree’s revenue ... the company has built its organization to more than 500 ...
(Date:6/19/2013)... Guests at the Residence Inn Scottsdale Paradise Valley ... go to bed or rise early thanks to a new ... , Crafty travelers will have a little extra change in ... Paradise Valley hotel’s Book Early and Save Up to ... notice, guests can enjoy the year-round Scottsdale sunshine in deluxe ...
Breaking Medicine News(10 mins):Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 3Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 2Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 3Health News:PREFERRED Therapy Providers, Inc. and WellCare of Arizona Finalize Their Agreement to Offer Medicare Advantage Plan to PREFERRED's Arizona Provider Network 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4
... of the BBVA Foundation, Francisco Gonzlez, Jose Baselga, ... Center (MGHCC), and Andrs de Kelety, Managing Director ... in Barcelona, yesterday signed the agreement creating the ... the event was the Foundation,s Director, Mr. Rafael ...
... (HealthDay News) -- Women and younger men account for a ... are less likely than older men to receive preventive medications ... Researchers evaluated more than 3,000 heart attack patients treated at ... and found that 70.3 percent of them had not been ...
... study to investigate the tolerability of the breast cancer drug ... stop taking their prescribed therapy early because of problems with ... of the research paper, published today in the cancer journal ... 64 male breast cancer patients at their institution who had ...
... rely on recombinant, protein-based drugs must often endure ... intravenous therapy. Researchers at Children,s Hospital Boston demonstrate ... engineered cells, could secrete the drug on demand ... issue of the journal Blood , they ...
... By Randy Dotinga HealthDay Reporter , TUESDAY, ... whole-body vibration doesn,t appear to improve the bone health ... osteoporosis. The treatment -- which involves standing on a ... -- showed promise in animals. But researchers, who hoped those ...
... read will be one of the topics of a conference ... co-sponsored by the UC Davis Center for Mind and Brain, ... Visual Learning, and the departments of psychology and linguistics at ... to read, said David Corina, professor in the Department of ...
Cached Medicine News:Health News:Mass. General Cancer Center and Vall d'Hebron Institute of Oncology biomarker alliance 2Health News:Mass. General Cancer Center and Vall d'Hebron Institute of Oncology biomarker alliance 3Health News:Women, Younger Men Under-Treated Before Heart Attack: Study 2Health News:Male breast cancer patients stop taking tamoxifen early because of drug-related side effects 2Health News:Male breast cancer patients stop taking tamoxifen early because of drug-related side effects 3Health News:Engineered, drug-secreting blood vessels reverse anemia in mice 2Health News:Engineered, drug-secreting blood vessels reverse anemia in mice 3Health News:Whole-Body Vibration Doesn't Build Bone After All: Study 2Health News:Visual language, cognition and deaf education topics of summit 2
(Date:6/19/2013)... , June 19, 2013   Voices Against ... finding a cure for brain cancer, today announced that ... grant to support the clinical investigation of Toca 511 ... high grade glioma brain cancer (Grade 3 or Grade ... novel treatments for advanced cancer, with an initial focus ...
(Date:6/19/2013)... DIEGO , June 19, 2013   Nektar Therapeutics ... results from a human abuse liability (HAL) study for ... rate of entry into the brain.  This slow rate of ... to the abuse of and addiction to current opioid analgesics. ... NKTR-181 was rated similar to placebo in "drug liking" ...
(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...
Breaking Medicine Technology:Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6
... Varian Medical Systems (NYSE: VAR ) ... U.S. Customs and Border Protection (CBP) for multiple IntellX® cargo ... company,s largest single order for Varian,s IntellX gantry systems. The ... vehicles for both border security and manifest verification purposes. ...
... 2011 DURECT Corporation (Nasdaq: DRRX ) ... (FDA) has accepted the resubmission of the New Drug ... KG ) and the PDUFA goal date ... ) REMOXY, based on DURECT,s ORADUR® technology, ...
Cached Medicine Technology:Varian Medical Systems' Security and Inspection Products Group Receives Largest Single Order for IntellX Systems 2REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 2REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 3
... the right features for assay development ... instrument control. Reduces the inevitable transfer ... HTS. Specifically developed to meet the ... AD delivers unparalleled detection performance for ...
... The POLARstar OPTIMA is a fully ... incorporates five different measurement principles:, , ... , Time-Resolved Fluorescence , High-Performance ... Absorbance ,It is designed ...
... of PCR, cDNA and Oligonucleotides The ... for a variety applications that are quantified by ... to handle assays in Microplate formats from ... Cuvettes Independent whether you have ...
The basic modular Wallac 1420 VICTOR2 is a manually operated platereader which enables luminometry, fluorometry and photometry measurements to be made....
Medicine Products: